艾昆纬：2025营养：肥胖症管理药物的基石：肥胖处方药兴起背后的消费者健康市场机遇白皮书（英文版）（20页）.pdf

1、White PaperNutrition as the Keystone for Obesity Management Medication The consumer health market opportunity behind the rise of obesity prescription medicinesVOLKER SPITZER,Vice President,Global R&D/RWE Services&Thought Leadership,IQVIA Consumer Health SARAH RICKWOOD,Vice President,EMEA Thought Lea

2、dership at IQVIATable of contentsIntroduction 1Nutrient intake and deficiency prevalence in GLP-1 RA users 2Dose-and duration-dependent effects 4Mechanisms underlying nutrient deficiencies 5Clinical consequences of deficiencies 6Mitigation strategies for nutritional health 8The role of the nutrition

3、 and medical nutrition industry 11Conclusion 14About the authors 15References 16 |12025 is a pivotal year for anti-obesity medications(AOMs),bridging the explosive growth of 2024 and the next wave of launches expected in 2026.The market,already surpassing$30Bn at list price levels in 2024,will see s

4、hifting dynamics across innovation,reimbursement,supply,and clinical understanding.1Key events include redefinition of clinical obesity by The Lancet Commission,multiple high-stakes phase 2/3 trial readouts,easing of supply shortages,and early real-world evidence accumulation.As competition intensif

5、ies,innovators must differentiate on efficacy,tolerability,and persistencewhile digital health support and physician education become critical levers.2025 will mark the transition from peak hype to a more structured,evidence-driven and competitive AOM market.1 Currently available AOMs are Glucagon-l

6、ike peptide-1 receptor agonists(GLP-1 RAs)and associated agentsincluding injectables like semaglutide(Ozempic/Wegovy),liraglutide(Victoza/Saxenda),and the injectable gastric inhibitory polypeptide(GIP)/GLP-1 receptor agonist tirzepatide(Zepbound/Mounjaro).They induce weight loss by suppressing appet